Ambrogio Francesca, Poli Melita Anna, Lospalluti Lucia, Lettini Teresa, Cassano Nicoletta, Vena Gino Antonio, Ingravallo Giuseppe, Cazzato Gerardo, Foti Caterina
Section of Dermatology and Venereology, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari "Aldo Moro", 70124 Bari, Italy.
Section of Molecular Pathology, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari "Aldo Moro", 70124 Bari, Italy.
J Clin Med. 2023 Dec 20;13(1):32. doi: 10.3390/jcm13010032.
The advent of tyrosine kinase inhibitors (TKIs) blocking BCR-ABL activity has revolutionized the therapeutic management of patients with chronic myeloid leukemia (CML). Adverse cutaneous reactions (ACRs) are common nonhematologic adverse events associated with the use of BCR-ABL TKIs. A characteristic pattern of eruption resembling keratosis pilaris (KP) has been described in patients treated with these drugs, especially nilotinib and dasatinib. The pathogenesis of this ACR is still unknown. This type of reaction appears to be uncommon with imatinib. Here, we report the case of an elderly patient with an asymptomatic KP-like eruption, which appeared one month after starting treatment with imatinib for CML. The case presentation is accompanied by a review of similar reactions in patients with CML treated with BCR-ABL inhibitors, attempting to make an excursus on the molecular targets of such drugs and possible mechanisms underlying this ACR.
酪氨酸激酶抑制剂（TKIs）阻断BCR-ABL活性的出现彻底改变了慢性髓性白血病（CML）患者的治疗管理。皮肤不良反应（ACRs）是与使用BCR-ABL TKIs相关的常见非血液学不良事件。在用这些药物治疗的患者中，尤其是尼罗替尼和达沙替尼，已经描述了一种类似于毛发角化病（KP）的特征性皮疹模式。这种ACR的发病机制仍然未知。这种类型的反应在伊马替尼治疗中似乎不常见。在此，我们报告一例老年患者，在开始使用伊马替尼治疗CML一个月后出现无症状的KP样皮疹。病例报告还伴有对接受BCR-ABL抑制剂治疗的CML患者类似反应的综述，试图探讨此类药物的分子靶点以及这种ACR潜在的可能机制。
